Therapeutic Pipeline
At Aurealcrat Inc., we have steadily deepened the science that underpins our computational discovery platform, strengthening its predictive power and expanding its reach across discovery and development. As these capabilities matured, our organization advanced in parallel—evolving from a tools-centric posture to an integrated, outcome-driven engine for therapeutic innovation.
To capture the full value of this platform for areas of significant unmet need, we established a dedicated therapeutics organization. Our pipeline embodies a disciplined, evidence-weighted approach that fuses physics-informed computation, AI-enabled modeling, and modern translational biology—advancing differentiated candidates with clear paths from hypothesis to the clinic.
Therapeutics Pipeline
Integrating physics-informed computation, AI, and translational biology to advance differentiated therapeutics.
Aurealcraft Ferroptosis Program Summary
Advancing next-generation therapies by harnessing ferroptosis to transform the fight against cancer and beyond.
AUR-ARF101 (GSR) — AUREXIS
Target: GSR (Glutathione Reductase)
Small-molecule program aimed at selectively inducing ferroptosis in tumor cells by lowering the cellular GSH/NADPH buffer via GR inhibition, thereby reducing the lipid peroxidation threshold.
AUR-ARF102 (GSR) — FERROVEXA
Target: GSR (Glutathione Reductase)
Series improving GR selectivity and cellular delivery through structure–activity relationships; validated by lipid peroxidation biomarkers and GSH/GSSG dynamics.
AUR-ARF510 (GSR) — AUREXIS
Target: GSR (Glutathione Reductase)
Sub-program integrating pharmacodynamics and pharmacokinetics of GR-centered ferroptosis modulation to evaluate in vivo efficacy and the safety window in advanced candidates.